Market news
YARDLEY, Pa., August 24, 2026--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9, 2026.
YARDLEY, Pa., August 20, 2026--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees.
Detailed price information for Savara Inc (SVRA-Q) from The Globe and Mail including charting and trades.
Detailed price information for Savara Inc (SVRA-Q) from The Globe and Mail including charting and trades.
LANGHORNE, Pa., August 11, 2026--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second quarter ending June 30, 2026 and provided a business update.
LANGHORNE, Pa., July 30, 2026--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO) has granted a patent covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). European patent No.4121000 provides protection for MOLBREEVI through March 2041. Separately, the Australian Patent Office has also
Detailed price information for Savara Inc (SVRA-Q) from The Globe and Mail including charting and trades.
SVRA advances Molbreevi with positive long-term phase III data, an FDA review on track and expanded patent protection supporting its commercial outlook.
This is the newest page. Registered accounts read further back.